Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by CancerSlayeron Jun 18, 2022 11:03pm

528 Views

Post# 34767211

A Better Vaccine Approach For Our Tech?

An intranasal &/or inhaled approach that offers both mucosal & systemic immunity....could this be the ticket for more durable immunity & immunity against variants? Interesting article below suggests this & opens the door for an opportunity to create a potentially more effective/durable aerosolized version.

Note: Injected/Intramuscular vaccines (i.e. the more commonly used mRNA vaccines by Pfizer & Moderna) can only provide systemic immunity

SamAfkhami15 Michael R.D’Agostino25 AliZhang2 Hannah D.Stacey2 ArtMarzok2 AlishaKang1 RamandeepSingh1 JegarubeeBavananthasivam1 GlukeYe1 XiangqianLuo13 FuanWang1 Jann C.Ang2 AnnaZganiacz1 UmaSankar1 NatalliaKazhdan1 Joshua F.E.Koenig1 AllyssaPhelps1 Steven F.Gameiro1 ShangguoTang4 ManelJordana1 YonghongWan1 Karen L.Mossman1 MangalakumariJeyanathan1 AmyGillgrass1 Maria Fe C.Medina1 FionaSmaill4 Brian D.Lichty1 Matthew S.Miller2 ZhouXing16

1: McMaster Immunology Research Centre, M.G. DeGroote Institute for Infectious Disease Research, Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada

2: McMaster Immunology Research Centre, M. G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada

3: Department of Pediatric Otolaryngology, Shenzhen Hospital, Southern Medical University, Shenzhen, China

4: Department of Pathology and Molecular Medicine, M.G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON L8S 4K1, Canada

Received 13 July 2021, Revised 16 December 2021, Accepted 2 February 2022, Available online 9 February 2022, Version of Record 3 March 2022.

Published: March 3, 2022

Summary

The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current COVID-19 vaccines administered intramuscularly and designed to only target the spike protein. There is a pressing need to develop next-generation vaccine strategies for broader and long-lasting protection. Using adenoviral vectors (Ad) of human and chimpanzee origin, we evaluated Ad-vectored trivalent COVID-19 vaccines expressing spike-1, nucleocapsid, and RdRp antigens in murine models. We show that single-dose intranasal immunization, particularly with chimpanzee Ad-vectored vaccine, is superior to intramuscular immunization in induction of the tripartite protective immunity consisting of local and systemic antibody responses, mucosal tissue-resident memory T cells and mucosal trained innate immunity. We further show that intranasal immunization provides protection against both the ancestral SARS-CoV-2 and two VOC, B.1.1.7 and B.1.351. Our findings indicate that respiratory mucosal delivery of Ad-vectored multivalent vaccine represents an effective next-generation COVID-19 vaccine strategy to induce all-around mucosal immunity against current and future VOC.